Login to Your Account

In The Clinic NEWS

DUBLIN – Bone Therapeutics SA is calling an early halt to a phase I/IIa trial of its Allob allogeneic cell therapy in patients with slow-to-heal bone fractures following an interim analysis that showed the therapy exceeded expectations.

Solid efficacy and a distinguishing safety profile – so far, anyway – should give Alnylam Pharmaceuticals Inc. and Sanofi SA an edge over competitor Ionis Pharmaceuticals Inc., analysts said, as the partnered pair scored a top-line phase III win testing RNAi therapy patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy.

Supernus Pharmaceuticals Inc. shares fell 23.4 percent Tuesday after the company dropped one of two doses of an experimental treatment for impulsive aggression in children with ADHD that it was evaluating in twin phase III studies.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: